PATIENTS suffering Irritable Bowel Syndrome (IBS) are being invited to join a Phase II double-blind, randomised, placebo controlled clinical trial, to investigate the efficacy and safety of an oral cannabidiol formulation for the condition.
The project is being led by SVG Pharmaceuticals, and involves CBD100 (Australian Natural Elan) delivered orally for a period of four weeks.
Prospective participants must be above 18 years of age at time of consent, and have suffered abdominal pain for at least one day per week for the prior three months with symptoms originating at least six months earlier.
The trial aims to achieve an S3 registration on Elan CBD Oil from Australian Natural Therapeutics Group (ANTG) - info@svgpharma.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jun 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jun 23
